MCID: URM002
MIFTS: 48

Uremia malady

Categories: Nephrological diseases

Aliases & Classifications for Uremia

Aliases & Descriptions for Uremia:

Name: Uremia 12 52 42 14 69
Uremia of Renal Origin 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4676
ICD10 33 N19
MeSH 42 D014511
UMLS 69 C0041948

Summaries for Uremia

MalaCards based summary : Uremia, also known as uremia of renal origin, is related to pericarditis and myocardial infarction. An important gene associated with Uremia is EPO (Erythropoietin), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Ca, cAMP and Lipid Signaling. The drugs Fexofenadine and Gabapentin have been mentioned in the context of this disorder. Affiliated tissues include kidney, testes and endothelial, and related phenotypes are homeostasis/metabolism and cardiovascular system

Wikipedia : 71 Uremia is the condition of having \"urea in the blood\". Urea is one of the primary components of urine.... more...

Related Diseases for Uremia

Diseases related to Uremia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 172)
id Related Disease Score Top Affiliating Genes
1 pericarditis 29.0 ALB CRP LPL RETN TNFRSF11B VWF
2 myocardial infarction 28.4 ALB APOC3 CRP RETN VWF
3 vitiligo mental retardation facial dysmorphism uremia 11.8
4 nephronophthisis 11.1
5 nephronophthisis 1, juvenile 10.9
6 hemolytic-uremic syndrome 10.8
7 euthyroid sick syndrome 10.8
8 autosomal dominant medullary cystic kidney disease with hyperuricemia 10.8
9 autosomal dominant medullary cystic kidney disease without hyperuricemia 10.8
10 gilles de la tourette syndrome 10.3 ALB B2M
11 stickler syndrome 10.3 PTH TNFRSF11B
12 striatonigral degeneration 10.2 ALB CASR PTH
13 plummer's disease 10.2 ALB B2M CRP
14 breast metaplastic carcinoma 10.2 B2M EPO PTH
15 intra-abdominal lymph node mast cell malignancy 10.2 CRP SPP1 TNFRSF11B
16 mitochondrial dna depletion syndrome 6 10.2 CASR SPP1 VDR
17 ischemic optic neuropathy 10.2 ALB CRP VWF
18 waardenburg syndrome, type 4b 10.2 CASR PTH VDR
19 anterior foramen magnum meningioma 10.2 ALB B2M EPO
20 gastric antral vascular ectasia 10.2 CASR PTH VDR
21 shoulder impingement syndrome 10.2 ALB CRP
22 hyperlipoproteinemia type iv 10.2 ALB CRP LEP
23 acrorenal syndrome 10.2 PTH TNFRSF11B VDR
24 deafness, autosomal recessive 79 10.2 CRP SPP1 VWF
25 y chromosome detection 10.2 PTH VDR
26 weill-marchesani syndrome 10.2 CASR PTH VDR
27 opioid abuse 10.2 CASR PTH VDR
28 pre-eclampsia 10.2 CASR PTH VDR
29 indian tick typhus 10.2 CASR PTH VDR
30 sclerosing adenosis of breast 10.2 ALB B2M CRP
31 parathyroid carcinoma 10.2 CASR PTH VDR
32 cerebral sarcoidosis 10.2 ALB EPO TF
33 poems syndrome 10.2 CRP EPO TF
34 congenital chloride diarrhea 10.2 ALB CRP VWF
35 ischemic bone disease 10.1 PTH TNFRSF11B VDR
36 spastic entropion 10.1 ALB CRP TF
37 cranial nerve palsy 10.1 B2M CRP TNFRSF11B
38 blind hypotensive eye 10.1 CRP EPO TF
39 atherosclerosis 10.1
40 malignant hyperthermia susceptibility 1 10.1 ALB B2M TF
41 ceroid lipofuscinosis, neuronal, kufs type, adult onset 10.1 CRP SPP1 TNFRSF11B VWF
42 dysbaric osteonecrosis 10.1 PTH SPP1 TNFRSF11B VDR
43 acrocephalopolydactyly 10.1 LEP RETN
44 tinea unguium 10.1 CASR PTH TNFRSF11B VDR
45 bladder papillary transitional cell neoplasm 10.1 B2M PTH TNFRSF11B
46 hyperparathyroidism 10.1
47 newborn respiratory distress syndrome 10.1 CASR SPP1 VDR
48 retinal arterial macroaneurysm with supravalvular pulmonic stenosis 10.1 ALB CRP EPO TF
49 bladder sarcoma 10.1 ALB LEP TF
50 neuronal ceroid-lipofuscinoses 10.1 ALB CRP EPO TF

Graphical network of the top 20 diseases related to Uremia:



Diseases related to Uremia

Symptoms & Phenotypes for Uremia

MGI Mouse Phenotypes related to Uremia:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 LPL PTH RETN SPP1 TF VDR
2 cardiovascular system MP:0005385 10.25 VWF B2M CRP EPO GHR LEP
3 cellular MP:0005384 10.24 ALB B2M CASR EPO GHR LEP
4 growth/size/body region MP:0005378 10.22 TF TNFRSF11B VDR AHSG B2M CASR
5 hematopoietic system MP:0005397 10.2 B2M CASR EPO GHR LEP PTH
6 immune system MP:0005387 10.18 B2M CASR CRP EPO GHR LEP
7 integument MP:0010771 9.97 SPP1 VDR B2M CASR EPO GHR
8 mortality/aging MP:0010768 9.97 ALB TNFRSF11B VDR VWF B2M CASR
9 limbs/digits/tail MP:0005371 9.87 LEP PTH TNFRSF11B VDR AHSG EPO
10 liver/biliary system MP:0005370 9.86 ALB B2M EPO GHR LEP LPL
11 muscle MP:0005369 9.61 AHSG ALB CASR EPO GHR LEP
12 skeleton MP:0005390 9.28 AHSG CASR EPO GHR LEP PTH

Drugs & Therapeutics for Uremia

Drugs for Uremia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 166)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fexofenadine Approved Phase 4 83799-24-0 3348
2
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
3
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
4
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
5
Glipizide Approved Phase 4 29094-61-9 3478
6
Metformin Approved Phase 4 657-24-9 14219 4091
7
Benzocaine Approved Phase 4 1994-09-7, 94-09-7 2337
8
Pamidronate Approved Phase 4 40391-99-9 4674
9
Liraglutide Approved Phase 4 204656-20-2
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
11
leucovorin Approved, Nutraceutical Phase 4 58-05-9 54575, 6560146 143
12
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
13
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
14 tannic acid Approved, Nutraceutical Phase 4
15 Analgesics Phase 4,Phase 3
16 Anti-Allergic Agents Phase 4
17 Anti-Anxiety Agents Phase 4
18 Anticonvulsants Phase 4
19 calcium channel blockers Phase 4
20 Calcium, Dietary Phase 4
21 Central Nervous System Depressants Phase 4
22 Histamine Antagonists Phase 4
23 Histamine H1 Antagonists Phase 4
24 Histamine H1 Antagonists, Non-Sedating Phase 4
25
Histamine Phosphate Phase 4 51-74-1 65513
26 Neurotransmitter Agents Phase 4
27 Peripheral Nervous System Agents Phase 4,Phase 3
28 Psychotropic Drugs Phase 4
29 Tranquilizing Agents Phase 4
30 Hormone Antagonists Phase 4,Phase 2
31 Hormones Phase 4,Phase 2
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2
33 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
34 Hematinics Phase 4
35 Micronutrients Phase 4,Phase 2
36 Trace Elements Phase 4,Phase 2
37 Vitamin B Complex Phase 4
38 Vitamins Phase 4,Phase 2
39 Antioxidants Phase 4,Phase 1,Phase 2
40 Protective Agents Phase 4,Phase 1,Phase 2
41 Polymethyl Methacrylate Phase 4
42 Vasodilator Agents Phase 4
43 Tocopherols Phase 4
44 Tocotrienols Phase 4
45 Hypoglycemic Agents Phase 4,Phase 2
46 Incretins Phase 4
47 Dialysis Solutions Phase 4,Phase 3,Phase 2
48 Folate Nutraceutical Phase 4
49 Vitamin B9 Nutraceutical Phase 4
50 Tocopherol Nutraceutical Phase 4

Interventional clinical trials:

(show top 50) (show all 95)
id Name Status NCT ID Phase
1 Probiotics Use in the Chronic Peritoneal Dialysis Patients Unknown status NCT01076426 Phase 4
2 Pregabalin for the Treatment of Uremic Pruritus Unknown status NCT01852318 Phase 4
3 Uremic Hyperhomocysteinemia -A Folate Trial for Possible Prevention of Cardiovascular Events Completed NCT00317005 Phase 4
4 Influence of Oral Vitamin C Supplement on the Inflammation Status in Dialysis Patients Completed NCT01356433 Phase 4
5 Uremic Pruritus, Cytokines and Polymethylmethacrylate Artificial Kidney Completed NCT00442819 Phase 4
6 Oxidative Stress and Hemodialysis Access Failure Completed NCT00410449 Phase 4
7 Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease Completed NCT00513630 Phase 4
8 Heat Disinfection of HD Water Treatment System in Hemodialysis Patients Completed NCT01138280 Phase 4
9 Hannover Dialysis Outcome Study Completed NCT00529139 Phase 4
10 Very Low Protein Diet or Dialysis in Uremic Elderly? Completed NCT00388648 Phase 4
11 A Clinical Trial of IntensiVE Dialysis Completed NCT00649298 Phase 4
12 Osteopenia and Renal Osteodystrophy: Evaluation and Management Completed NCT00108394 Phase 4
13 Liraglutide Treatment to Patients With Severe Renal Insufficiency Completed NCT01394341 Phase 4
14 STUDY OF GLUCOSE IN DIALYSIS WATER WITH REGARD TO BLOOD PRESSURE AND QUALITY OF LIFE Completed NCT00278057 Phase 4
15 Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS Recruiting NCT02574403 Phase 4
16 Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment Enrolling by invitation NCT02614898 Phase 4
17 Nafamostat Efficacy and Safety in Critically Ill Patients(NICE) Unknown status NCT01486485 Phase 3
18 The Effect and Safety of Hemodialysis and Hemoperfusion on Severe Renal Osteopathy and Itching in Uremia Patients Completed NCT02747979 Phase 2, Phase 3
19 Effects of Convective Therapies in Dialysis Patients Completed NCT01583309 Phase 3
20 Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS) Completed NCT01410916 Phase 2, Phase 3
21 Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS) Recruiting NCT02949128 Phase 3
22 Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU Recruiting NCT02205541 Phase 3
23 Effects of Short-chain Fatty Acids on Inflammatory and Metabolic Parameters in Maintenance Hemodialysis Not yet recruiting NCT02976688 Phase 2, Phase 3
24 Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) Not yet recruiting NCT03131219 Phase 3
25 Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome Terminated NCT00004465 Phase 3
26 The Plasma Large-Volume Exchange RCT Withdrawn NCT01433003 Phase 3
27 Effect of SVF Derived MSC in DCD Renal Transplantation Unknown status NCT02492490 Phase 1, Phase 2
28 Clonal Deletion on Living-Relative Donor Kidney Transplantation Unknown status NCT01408797 Phase 1, Phase 2
29 Treatment of Uremic Pruritus by Olive-omega 3 Ointment Unknown status NCT01447693 Phase 1, Phase 2
30 Safety and Efficacy of BMMNC in Patients With Chronic Renal Failure Unknown status NCT01876017 Phase 1, Phase 2
31 Rituximab in Patients With Relapsed or Refractory TTP-HUS Unknown status NCT00531089 Phase 2
32 L-Cysteine in Peritoneal Dialysis Completed NCT02050139 Phase 2
33 Clinical and Biochemical Effects of Multipass Hemodialysis Completed NCT01267760 Phase 2
34 Omega-3 Fatty Acid Administration in Dialysis Patients Completed NCT00655525 Phase 2
35 Vitamin D, Insulin Resistance and Inflammation in ESRD Completed NCT00656032 Phase 2
36 Role of Turmeric on Oxidative Modulation in ESRD Patients Completed NCT01906840 Phase 1, Phase 2
37 Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome Completed NCT00309257 Phase 2
38 Sevelamer in Proteinuric CKD Completed NCT01968759 Phase 2
39 A Study in Patients With End-Stage Renal Disease Completed NCT01200290 Phase 2
40 The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS) Completed NCT01757431 Phase 2
41 An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome Completed NCT01194973 Phase 2
42 An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome Completed NCT01193348 Phase 2
43 Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS Completed NCT00844844 Phase 2
44 Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS Completed NCT00844545 Phase 2
45 Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS Completed NCT00844428 Phase 2
46 Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS) Completed NCT00838513 Phase 2
47 Induction With SVF Derived MSC in Living-related Kidney Transplantation Recruiting NCT02492308 Phase 1, Phase 2
48 Modulation of Gut Microbiota in End-stage Renal Disease Not yet recruiting NCT02568891 Phase 2
49 Effect of BM-MSCs in DCD Kidney Transplantation Not yet recruiting NCT02561767 Phase 1, Phase 2
50 Metabolic Effects of Thiazolidinediones in Chronic Kidney Disease Terminated NCT00368017 Phase 2

Search NIH Clinical Center for Uremia

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: uremia

Genetic Tests for Uremia

Anatomical Context for Uremia

MalaCards organs/tissues related to Uremia:

39
Kidney, Testes, Endothelial, Bone, Monocytes, Neutrophil, Heart

Publications for Uremia

Articles related to Uremia:

(show top 50) (show all 674)
id Title Authors Year
1
Increased Neutrophil Extracellular Trap Formation in Uremia Is Associated with Chronic Inflammation and Prevalent Coronary Artery Disease. ( 28523279 )
2017
2
Persistence of Vascular Calcification after Reversal of Uremia. ( 27939134 )
2017
3
Co-Expression Analysis of Blood Cell Genome Expression to Preliminary Investigation of Regulatory Mechanisms in Uremia. ( 28050009 )
2017
4
Back to the future: restricted protein intake for conservative management of CKD, triple goals of renoprotection, uremia mitigation, and nutritional health. ( 26886110 )
2016
5
Lion face in a uremia patient. ( 28011855 )
2016
6
Development of Acute Pericarditis Associated with New-onset Rheumatoid Arthritis in a Diabetic Patient with Renal Impairment: The Elusive Nature of Uremia. ( 27086811 )
2016
7
Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target. ( 26590448 )
2016
8
Epidemiology and Mechanisms of Uremia-Related Cardiovascular Disease. ( 26831434 )
2016
9
Effect of chronic uremia on the transcriptional profile of the calcified aorta analyzed by RNA sequencing. ( 26739890 )
2016
10
MRI Findings of Syndrome of Acute Bilateral Symmetrical Basal Ganglia Lesions in Diabetic Uremia: A Case Report and Literature Review. ( 27493824 )
2016
11
Uremia-caused changes of ghrelin system in hippocampus may be associated with impaired cognitive function of hippocampus. ( 26861060 )
2016
12
Effect of 1,25-(OH)2D3 and lipopolysaccharide on mononuclear cell inflammation in type 2 diabetes mellitus and diabetic nephropathy uremia. ( 27706649 )
2016
13
Vascular Calcification in Uremia: New-Age Concepts about an Old-Age Problem. ( 26676134 )
2016
14
Comparison of HLA-A, -B and -DRB1 Loci Polymorphism between Kidney Transplants of Uremia Patients and Healthy Individuals in Central China. ( 27780235 )
2016
15
Comparing classification performance of several types of significant genes to identify key genes in uremia. ( 27383319 )
2016
16
Ptosis and uremia as a rare feature of uremia. ( 27728481 )
2016
17
Electronegative Low-density Lipoprotein Increases Coronary Artery Disease Risk in Uremia Patients on Maintenance Hemodialysis. ( 26765403 )
2016
18
A Comparison between Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Eradication in Patients with Uremia: A Randomized Clinical Trial. ( 26933480 )
2016
19
Outcome of End-Stage Renal Disease Patients with Advanced Uremia and Acidemia. ( 26787028 )
2016
20
Berberine Reduces Uremia-associated Intestinal Mucosal Barrier Damage. ( 27506986 )
2016
21
DNA methylation profiling reveals differences in the 3 human monocyte subsets and identifies uremia to induce DNA methylation changes during differentiation. ( 27018948 )
2016
22
Urea transporters and sweat response to uremia. ( 27273880 )
2016
23
Differential Expression of Lipoprotein-Associated Phospholipase A2 in Monocyte Subsets: Impact of Uremia and Atherosclerosis. ( 27992874 )
2016
24
Inhibiting post-translational core fucosylation prevents vascular calcification in the model of uremia. ( 27521658 )
2016
25
Signaling of Serum Amyloid A Through Receptor for Advanced Glycation End Products as a Possible Mechanism for Uremia-Related Atherosclerosis. ( 26988587 )
2016
26
Effectiveness of posthemodialysis administration of pregabalin (75 mg) in treatment resistance uremia pruritus. ( 26957874 )
2016
27
Uremia-Associated Premature Ageing Of T Cells Does Not Predict Infectious Complications After Renal Transplantation. ( 26914971 )
2016
28
Myocardial bioenergetic abnormalities in experimental uremia. ( 27307758 )
2016
29
Sweating in Systemic Abnormalities: Uremia and Diabetes Mellitus. ( 27584963 )
2016
30
An empirical study of a hybrid imbalanced-class DT-RST classification procedure to elucidate therapeutic effects in uremia patients. ( 27053166 )
2016
31
Posterior Reversible Encephalopathy Syndrome in a Patient with Severe Uremia without Hypertension. ( 26726088 )
2016
32
Study on 3'-UTR length polymorphism in peripheral blood mononuclear cells of uremia patient. ( 26554293 )
2015
33
Pseudotumor cerebri associated with uremia and NSAIDs. ( 26022039 )
2015
34
Anti-inflammatory effects of 1,25-dihydroxyvitaminA D3A in monocytes cultured in serum from patients with typeA 2 diabetes mellitus and diabetic nephropathy with uremia via Toll-like receptorA 4 and nuclear factor-I_B p65. ( 26497229 )
2015
35
Altered Renal Expression of Relevant Clinical Drug Transporters in Different Models of Acute Uremia in Rats. Role of Urea Levels. ( 26065488 )
2015
36
Uremic myopathy: is oxidative stress implicated in muscle dysfunction in uremia? ( 25870564 )
2015
37
The Aryl Hydrocarbon Receptor is a Critical Regulator of Tissue Factor Stability and an Antithrombotic Target in Uremia. ( 26019318 )
2015
38
The serum levels of MMP-9, MMP-2 and vWF in patients with low doses of urokinase peritoneal dialysis decreased uremia complicated with cerebral infarction. ( 26550224 )
2015
39
Chorea due to diabetic hyperglycemia and uremia: distinct clinical and imaging features. ( 25649292 )
2015
40
Intratympanic steroid injection as a first-line therapy in uremia patients with sudden sensorineural hearing loss. ( 25783847 )
2015
41
Macrophages Are Involved in Gut Bacterial Translocation and Reversed by Lactobacillus in Experimental Uremia. ( 26518418 )
2015
42
Thrombotic Role of Blood and Endothelial Cells in Uremia through Phosphatidylserine Exposure and Microparticle Release. ( 26580207 )
2015
43
Clinical trials in uremia-time to reappraise. ( 25497457 )
2015
44
Oral manifestations in chronic uremia patients. ( 26513593 )
2015
45
Effect of Chronic Uremia on the Cell Surface Expression of B7 Family Costimulatory Molecules in an HLA-A2 Transgenic Mouse Model of Chronic Kidney Disease. ( 26310460 )
2015
46
Parathyroid-specific deletion of dicer-dependent microRNAs abrogates the response of the parathyroid to acute and chronic hypocalcemia and uremia. ( 26054367 )
2015
47
Aging and uremia: Is there cellular and molecular crossover? ( 25664244 )
2015
48
Reverse Left Ventricular Remodeling AfterA Kidney Transplantation: Unraveling the Complex Autointoxication of Uremia. ( 26483102 )
2015
49
The fibroblast growth factor receptor mediates the increased FGF23 expression in acute and chronic uremia. ( 26311115 )
2015
50
Soluble guanylate cyclase stimulator BAY 41-8543 and female sex ameliorate uremic aortic remodeling in a rat model of mild uremia. ( 26176653 )
2015

Variations for Uremia

Expression for Uremia

Search GEO for disease gene expression data for Uremia.

Pathways for Uremia

GO Terms for Uremia

Cellular components related to Uremia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.83 AHSG ALB APOC3 B2M CRP EPO
2 endoplasmic reticulum lumen GO:0005788 9.65 AHSG ALB B2M SPP1 TF
3 cell surface GO:0009986 9.63 B2M CASR EPO GHR LPL TF
4 platelet alpha granule lumen GO:0031093 9.54 AHSG ALB VWF
5 extracellular space GO:0005615 9.47 AHSG ALB APOC3 B2M CRP EPO
6 very-low-density lipoprotein particle GO:0034361 9.46 APOC3 LPL
7 chylomicron GO:0042627 9.43 APOC3 LPL
8 HFE-transferrin receptor complex GO:1990712 9.4 B2M TF
9 extracellular exosome GO:0070062 10.02 AHSG ALB APOC3 B2M CRP LPL

Biological processes related to Uremia according to GeneCards Suite gene sharing:

(show all 21)
id Name GO ID Score Top Affiliating Genes
1 post-translational protein modification GO:0043687 9.9 AHSG ALB SPP1 TF
2 response to drug GO:0042493 9.87 B2M LPL PTH TNFRSF11B
3 cellular calcium ion homeostasis GO:0006874 9.69 CASR PTH VDR
4 response to nutrient GO:0007584 9.67 EPO LEP TNFRSF11B
5 skeletal system development GO:0001501 9.62 AHSG PTH TNFRSF11B VDR
6 response to vitamin D GO:0033280 9.59 PTH SPP1
7 positive regulation of receptor-mediated endocytosis GO:0048260 9.58 B2M TF
8 positive regulation of JAK-STAT cascade GO:0046427 9.58 GHR LEP
9 high-density lipoprotein particle remodeling GO:0034375 9.56 ALB APOC3
10 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.55 EPO GHR
11 iron ion transport GO:0006826 9.54 B2M TF
12 lipoprotein metabolic process GO:0042157 9.54 ALB APOC3 LPL
13 intestinal absorption GO:0050892 9.52 LEP VDR
14 negative regulation of lipid storage GO:0010888 9.48 CRP LEP
15 chylomicron remodeling GO:0034371 9.46 APOC3 LPL
16 response to fibroblast growth factor GO:0071774 9.43 CASR PTH
17 retina homeostasis GO:0001895 9.43 ALB B2M TF
18 cellular response to iron ion GO:0071281 9.4 B2M TF
19 acute-phase response GO:0006953 9.33 AHSG CRP EPO
20 platelet degranulation GO:0002576 9.26 AHSG ALB TF VWF
21 cellular protein metabolic process GO:0044267 9.02 AHSG ALB B2M SPP1 TF

Molecular functions related to Uremia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 peptide hormone receptor binding GO:0051428 8.96 LEP PTH
2 hormone activity GO:0005179 8.92 EPO LEP PTH RETN

Sources for Uremia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....